The device, which contains flexible metal coils, is implanted into a woman’s fallopian tubes. After three months, tissue grows around the coils, blocking sperm from reaching eggs, thereby preventing pregnancy.
The warning reminds women to use an alternate form of birth control for the first three months after being implanted with the device and also lists various risks associated with Essure.
The FDA hopes the updated label will ensure women understand the benefits and risks associated with the permanent control device.
More articles on supply chain:
Supply chain tip of the week: Direct users to correct formularies
Novartis considers selling eye division
UPS workers vote to strike over health benefits: 5 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
